The effect of 6-mercaptopurine on natural killer-cell activities in Crohn's disease
dc.contributor.author | Korelitz, B. | en_US |
dc.contributor.author | Oliver, M. | en_US |
dc.contributor.author | Brogan, M. | en_US |
dc.contributor.author | Hiserodt, J. C. | en_US |
dc.contributor.author | Stevens, R. | en_US |
dc.contributor.author | Targan, S. | en_US |
dc.date.accessioned | 2006-09-11T15:21:10Z | |
dc.date.available | 2006-09-11T15:21:10Z | |
dc.date.issued | 1985-05 | en_US |
dc.identifier.citation | Brogan, M.; Hiserodt, J.; Oliver, M.; Stevens, R.; Korelitz, B.; Targan, S.; (1985). "The effect of 6-mercaptopurine on natural killer-cell activities in Crohn's disease." Journal of Clinical Immunology 5(3): 204-211. <http://hdl.handle.net/2027.42/44846> | en_US |
dc.identifier.issn | 1573-2592 | en_US |
dc.identifier.issn | 0271-9142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/44846 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=3874211&dopt=citation | en_US |
dc.description.abstract | Crohn's disease patients on long-term 6-mercaptopurine therapy (more than 4 months) were evaluated for activity of peripheral blood natural killer cells. Natural killer-cell cytolytic activity against K-562 tumor-cell targets was examined, as was natural killer-cell suppression of lymphoblastoid B-cell antibody production. In addition, these patients were studied for their ability to generate antitetanus-specific IgG antibody-producing lymphoblastoid B cells following in vivo booster immunization. Crohn's disease patients on 6-mercaptopurine therapy had significant reductions in peripheral blood natural killer-cell activity against K-562 targets compared to normals, disease controls, and Crohn's disease patients not on 6-mercaptopurine. Natural killer-cell suppression of lymphoblastoid B-cell antibody production was like-wise decreased in 6-mercaptopurine-treated patients compared to normal controls. In contrast, the in vivo generated lymphoblastoid B-cell antibody responses of Crohn's disease patients on 6-mercaptopurine therapy were not decreased compared to normal, while Crohn's disease patients not on 6-mercaptopurine therapy had significantly impaired IgG antitetanus antibody responses. These findings suggest that 6-mercaptopurine therapy in Crohn's disease affects several lymphoid subpopulations, resulting in a decreased natural killer-cell cytotoxic activity against K-562 target cells and a decreased natural killer-cell ability to suppress lymphoblastoid B-cell antibody production, as well as an improved humoral immune response following tetanus toxoid booster immunization. | en_US |
dc.format.extent | 924673 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Media | en_US |
dc.subject.other | Immunology | en_US |
dc.subject.other | Crohn's Disease | en_US |
dc.subject.other | 6-Mercaptopurine | en_US |
dc.subject.other | Biomedicine | en_US |
dc.subject.other | Medical Microbiology | en_US |
dc.subject.other | Internal Medicine | en_US |
dc.subject.other | Infectious Diseases | en_US |
dc.subject.other | Natural Killer Cells | en_US |
dc.subject.other | Suppressor Cells | en_US |
dc.subject.other | Antibody-producing Cells | en_US |
dc.title | The effect of 6-mercaptopurine on natural killer-cell activities in Crohn's disease | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Microbiology and Immunology | en_US |
dc.subject.hlbtoplevel | Science | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pathology, University of Michigan Medical Center, 48105, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Department of Medicine, Microbiology and Immunology, UCLA School of Medicine, V.A. Wadsworth Medical Center, 90024, Los Angeles, California | en_US |
dc.contributor.affiliationother | Department of Medicine, Microbiology and Immunology, UCLA School of Medicine, V.A. Wadsworth Medical Center, 90024, Los Angeles, California | en_US |
dc.contributor.affiliationother | Department of Medicine, Microbiology and Immunology, UCLA School of Medicine, V.A. Wadsworth Medical Center, 90024, Los Angeles, California | en_US |
dc.contributor.affiliationother | Department of Gastroenterology, Lennox Hill Hospital, 10021, New York, New York | en_US |
dc.contributor.affiliationother | Department of Medicine, Microbiology and Immunology, UCLA School of Medicine, V.A. Wadsworth Medical Center, 90024, Los Angeles, California; Department of Medicine, Center for the Health Sciences, UCLA School of Medicine, 90024, Los Angeles, California | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 3874211 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/44846/1/10875_2004_Article_BF00915512.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1007/BF00915512 | en_US |
dc.identifier.source | Journal of Clinical Immunology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.